)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Alligator Bioscience
Alligator Bioscience (ATORX) investor relations material
Alligator Bioscience Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Feb, 2026
Executive summary
Landmark 30-month survival data in phase II mitazalimab trial for pancreatic cancer, with 21% survival vs. 5% for chemotherapy alone and five complete responders; drug is phase III ready with regulatory alignment in the US and EU and ongoing partner discussions.
HLX22 program, developed by Henlius, shows strong phase II data in gastric cancer, is expanding into global phase III and additional breast cancer trials, and has Orphan Drug Designation in the US and EU.
Rights issue completed, raising SEK 91 million gross, with additional financing options and warrants for potential capital in 2026; loan terms renegotiated to extend maturity and reduce liabilities.
Expanded scientific foundation with key publications and presentations for mitazalimab and ATOR-4066, and US patent granted for ATOR-4066.
Reverse share split and changes in share capital structure executed.
Financial highlights
Net sales for Q4 2025: SEK 41.8 million, up from SEK 0.5 million in Q4 2024; full year 2025: SEK 57.8 million.
Operating loss for Q4 2025: SEK -22.5 million; full year 2025: SEK -105.8 million.
Loss for the period Q4 2025: SEK -29.0 million; full year 2025: SEK -51.4 million.
Cash and cash equivalents at year-end: SEK 62.2 million, with proceeds from rights issue received.
TO-14 warrants could raise up to SEK 61 million gross, with subscription period in March.
Outlook and guidance
Current liquidity extends runway to Q2 2026; management is exploring further financing and partnership options, with Moelis as transaction advisor.
Phase III mitazalimab trial in pancreatic cancer planned, with recruitment expected to take 18–24 months and interim analysis about a year later.
Randomized phase II study in biliary tract cancer to start in Q2, with potential for phase III expansion.
Continued cost control and prioritization of activities to strengthen regulatory and scientific position.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Alligator Bioscience earnings date
Q1 20265 May, 2026
Alligator Bioscience
Next Alligator Bioscience earnings date
Q1 20265 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage